GALWAY, Ireland – September 10, 2026 – Medtronic, a global leader in healthcare technology, announced the first clinical procedures using the Stealth AXiS™ surgical system across Europe, marking an important milestone as surgeons begin clinical use of the system across the region.
Medtronic announces first procedures in Europe with Stealth AXiS™ Surgical System
3 min read Premium comments
MedtronicEuropeStealth AXiS surgical system
The initial procedures include spine procedures, providing early clinical experience with a platform that integrates AI-driven surgical planning, real-time navigation and robotic-assisted execution.
"This technology represents a significant step forward in the way we undertake some of the most complex spinal procedures. Revision surgery of this nature can be exceptionally challenging due to the presence of existing implants and altered anatomy. The precision offered by Stealth AXiS™ system enables us to plan meticulously and execute that plan with greater confidence, accuracy and efficiency. Ultimately, the greatest benefit is for our patients, helping us deliver the safest possible surgery while pushing the boundaries of what can be achieved in complex spinal care," said Mr. Sean Molloy, Consultant Spinal Surgeon at Royal National Orthopaedic Hospital (RNOH), United Kingdom.
The Stealth AXiS™ system is part of Medtronic’s AiBLE™ smart ecosystem, which connects technologies and information across the surgical journey, from planning through the procedure and beyond. The system is designed to support an integrated approach to surgical care across spine and cranial procedures.
“The first procedures in Europe mark an important next step for the Stealth AXiS™ system as we expand access to this technology across the region,” said Oli Prosperi, Vice President, International Commercial, Cranial & Spinal Technologies, Medtronic. “With surgeons and clinical teams across multiple countries beginning to work with the system in spine and cranial procedures, we are excited to see this technology being used in clinical practice. We are proud to partner with these teams and look forward to building on this milestone together.”
Additional procedures are planned in the coming weeks, building on the early clinical experience with the Stealth AXiS™ surgical system.
For more information about the Stealth AXiS™ surgical system and the AiBLE™ smart ecosystem, visit our website.
About the Cranial & Spinal Technologies Business at Medtronic
As the global market leader, Medtronic Cranial and Spinal Technologies is transforming the standard of care in spine and cranial surgery by putting patients first and addressing the complex challenges faced by spine and neurosurgeons. With a portfolio of 150 products covering more than 20 pathologies, we serve over 4 million patients annually. Building on a legacy of innovation, our AiBLE™ ecosystem integrates advanced technologies, data, and AI with a patient-centric approach, offering customizable solutions to enhance surgical precision, improve workflow efficiency, and achieve better outcomes, before, during, and beyond surgery.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts:
Maria Trenzado
Communications for Western Europe
maria.trenzado@medtronic.com
Ingrid Goldberg
Investor Relations
+1-763-505-2696
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Medtronic's strategic expansion of the Stealth AXiS™ system into Europe marks a significant market entry for its AI-driven surgical platform. This move leverages its AiBLE™ smart ecosystem, aiming to enhance surgical precision and efficiency in complex spine and cranial procedures, potentially impacting market share and competitive dynamics in the region.
- Market expansion into Europe for the Stealth AXiS™ system, integrating AI-driven planning, real-time navigation, and robotic assistance.
- Part of Medtronic’s AiBLE™ smart ecosystem, strategically connecting technologies for an integrated surgical approach across spine and cranial care.
PhD Lens: Clinical and outcomes impact
The Stealth AXiS™ surgical system, now clinically used in Europe, integrates AI-driven planning, real-time navigation, and robotic assistance for complex spinal procedures. This technology aims to improve precision, particularly in revision surgeries with altered anatomy, potentially enhancing patient safety and surgical outcomes by enabling meticulous execution.
- Integrates AI-driven surgical planning, real-time navigation, and robotic-assisted execution for complex spine and cranial procedures.
- Designed to enhance precision in challenging cases like revision spine surgery, addressing altered anatomy and existing implants for improved safety.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.